Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89


Ultrasound-guided direct delivery of 3-bromopyruvate blocks tumor progression in an orthotopic mouse model of human pancreatic cancer.

Ota S, Geschwind JF, Buijs M, Wijlemans JW, Kwak BK, Ganapathy-Kanniappan S.

Target Oncol. 2013 Jun;8(2):145-51. doi: 10.1007/s11523-013-0273-x. Epub 2013 Mar 26.


Antiglycolytic therapy combined with an image-guided minimally invasive delivery strategy for the treatment of breast cancer.

Buijs M, Wijlemans JW, Kwak BK, Ota S, Geschwind JF.

J Vasc Interv Radiol. 2013 May;24(5):737-43. doi: 10.1016/j.jvir.2013.01.013. Epub 2013 Mar 13.


Systemic delivery of microencapsulated 3-bromopyruvate for the therapy of pancreatic cancer.

Chapiro J, Sur S, Savic LJ, Ganapathy-Kanniappan S, Reyes J, Duran R, Thiruganasambandam SC, Moats CR, Lin M, Luo W, Tran PT, Herman JM, Semenza GL, Ewald AJ, Vogelstein B, Geschwind JF.

Clin Cancer Res. 2014 Dec 15;20(24):6406-17. doi: 10.1158/1078-0432.CCR-14-1271. Epub 2014 Oct 17.


Separate and concurrent use of 2-deoxy-D-glucose and 3-bromopyruvate in pancreatic cancer cells.

Xiao H, Li S, Zhang D, Liu T, Yu M, Wang F.

Oncol Rep. 2013 Jan;29(1):329-34. doi: 10.3892/or.2012.2085. Epub 2012 Oct 17.


Human hepatocellular carcinoma in a mouse model: assessment of tumor response to percutaneous ablation by using glyceraldehyde-3-phosphate dehydrogenase antagonists.

Ganapathy-Kanniappan S, Kunjithapatham R, Torbenson MS, Rao PP, Carson KA, Buijs M, Vali M, Geschwind JF.

Radiology. 2012 Mar;262(3):834-45. doi: 10.1148/radiol.11111569.


Enhanced antitumor activity of 3-bromopyruvate in combination with rapamycin in vivo and in vitro.

Zhang Q, Pan J, Lubet RA, Komas SM, Kalyanaraman B, Wang Y, You M.

Cancer Prev Res (Phila). 2015 Apr;8(4):318-26. doi: 10.1158/1940-6207.CAPR-14-0142. Epub 2015 Feb 2.


Inhibitory effects of 3-bromopyruvate in human nasopharyngeal carcinoma cells.

Zou X, Zhang M, Sun Y, Zhao S, Wei Y, Zhang X, Jiang C, Liu H.

Oncol Rep. 2015 Oct;34(4):1895-904. doi: 10.3892/or.2015.4147. Epub 2015 Jul 23.


Systemic administration of 3-bromopyruvate in treating disseminated aggressive lymphoma.

Schaefer NG, Geschwind JF, Engles J, Buchanan JW, Wahl RL.

Transl Res. 2012 Jan;159(1):51-7. doi: 10.1016/j.trsl.2011.08.008. Epub 2011 Sep 22.


Intraarterial therapy with a new potent inhibitor of tumor metabolism (3-bromopyruvate): identification of therapeutic dose and method of injection in an animal model of liver cancer.

Vali M, Liapi E, Kowalski J, Hong K, Khwaja A, Torbenson MS, Georgiades C, Geschwind JF.

J Vasc Interv Radiol. 2007 Jan;18(1 Pt 1):95-101.


Synergistic antipancreatic tumor effect by simultaneously targeting hypoxic cancer cells with HSP90 inhibitor and glycolysis inhibitor.

Cao X, Bloomston M, Zhang T, Frankel WL, Jia G, Wang B, Hall NC, Koch RM, Cheng H, Knopp MV, Sun D.

Clin Cancer Res. 2008 Mar 15;14(6):1831-9. doi: 10.1158/1078-0432.CCR-07-1607.


Triptolide induces pancreatic cancer cell death via inhibition of heat shock protein 70.

Phillips PA, Dudeja V, McCarroll JA, Borja-Cacho D, Dawra RK, Grizzle WE, Vickers SM, Saluja AK.

Cancer Res. 2007 Oct 1;67(19):9407-16.


Inhibitory effects of 3-bromopyruvate on human gastric cancer implant tumors in nude mice.

Xian SL, Cao W, Zhang XD, Lu YF.

Asian Pac J Cancer Prev. 2014;15(7):3175-8.


A novel small-molecule inhibitor of protein kinase D blocks pancreatic cancer growth in vitro and in vivo.

Harikumar KB, Kunnumakkara AB, Ochi N, Tong Z, Deorukhkar A, Sung B, Kelland L, Jamieson S, Sutherland R, Raynham T, Charles M, Bagherzadeh A, Foxton C, Boakes A, Farooq M, Maru D, Diagaradjane P, Matsuo Y, Sinnett-Smith J, Gelovani J, Krishnan S, Aggarwal BB, Rozengurt E, Ireson CR, Guha S.

Mol Cancer Ther. 2010 May;9(5):1136-46. doi: 10.1158/1535-7163.MCT-09-1145. Epub 2010 May 4. Erratum in: Mol Cancer Ther. 2010 Jul;9(7):2153. Bagherazadeh, Azadeh [corrected to Bagherzadeh, Azadeh].


Effect of Src kinase inhibition on metastasis and tumor angiogenesis in human pancreatic cancer.

Ischenko I, Guba M, Yezhelyev M, Papyan A, Schmid G, Green T, Fennell M, Jauch KW, Bruns CJ.

Angiogenesis. 2007;10(3):167-82. Epub 2007 May 8.


Matrine inhibits proliferation and induces apoptosis of pancreatic cancer cells in vitro and in vivo.

Liu T, Song Y, Chen H, Pan S, Sun X.

Biol Pharm Bull. 2010;33(10):1740-5.


In vitro and in vivo anticancer efficacy of silibinin against human pancreatic cancer BxPC-3 and PANC-1 cells.

Nambiar D, Prajapati V, Agarwal R, Singh RP.

Cancer Lett. 2013 Jun 28;334(1):109-17. doi: 10.1016/j.canlet.2012.09.004. Epub 2012 Sep 26.


Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer.

Banerjee S, Zhang Y, Ali S, Bhuiyan M, Wang Z, Chiao PJ, Philip PA, Abbruzzese J, Sarkar FH.

Cancer Res. 2005 Oct 1;65(19):9064-72.


Apoptosis-inducing antitumor efficacy of hexokinase II inhibitor in hepatocellular carcinoma.

Kim W, Yoon JH, Jeong JM, Cheon GJ, Lee TS, Yang JI, Park SC, Lee HS.

Mol Cancer Ther. 2007 Sep;6(9):2554-62.


Plumbagin, isolated from Plumbago zeylanica, induces cell death through apoptosis in human pancreatic cancer cells.

Chen CA, Chang HH, Kao CY, Tsai TH, Chen YJ.

Pancreatology. 2009;9(6):797-809. doi: 10.1159/000210028. Epub 2010 Jan 28.


Supplemental Content

Support Center